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Temsirolimus has been demonstrated to result in signiﬁcant disease stabilization in children with high-
grade glioma, neuroblastoma, and rhabdomyosarcoma. While mucositis has been reported as a common
adverse effect of temsirolimus therapy in adult and pediatric patients, bowel perforation is an infrequent
and life-threatening side effect of temsirolimus in adults and has not previously been reported in
children. We present a child treated with temsirolimus for recurrent metastatic rhabdomyosarcoma who
underwent ileocecectomy and small bowel resection for perforationwith frank necrosis. His presentation
was complicated by Clostridium septicum infection, a rare, frequently fatal, gastrointestinal pathogen
associated with malignancy and bowel ischemia.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Temsirolimus is an ester of sirolimus (rapamycin) and a highly
speciﬁc inhibitor of mammalian target of rapamycin (mTOR). In-
hibition of mTOR reduces expression of vascular endothelial growth
factor (VEGF) via inhibition of hypoxia-inducible factor alpha-1
(HIF-1a), an important pro-angiogenic factor. Temsirolimus has
potent antitumor activity and is approved by the United States Food
and Drug Administration (FDA) for the treatment of advanced renal
cell carcinoma [1]. Several mTOR inhibitors, including temsir-
olimus, have demonstrated signiﬁcant antitumor activity in both in
vivo and in vitro pediatric solid tumor models, including rhabdo-
myosarcoma [2,3]. A recent phase I/II study of temosirolimus
monotherapy for relapsed high-grade glioma, neuroblastoma, or
rhabdomyosarcoma resulted in disease stabilization [4].
Mucositis has been reported as a common adverse effect of
temsirolimus therapy in both adult [5e8] and pediatric patients
[4,9,10]. In the report summarizing the FDA’s approval of the drugnited States Food and Drug
a-1; IFN-a, interferon-alpha;
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edicine, Section of Pediatric
l.: þ1 203 785 2701; fax: þ1
.R. Christison-Lagay).
Inc. This is an open access article ufor treatment of advanced renal cell carcinoma (RCC), mucositis
occurred more commonly in patients receiving temsirolimus (41%)
than in those receiving interferon-alpha (IFN-a) (10%) [5]. Bagatell
et al. reported one pediatric patient with grade 3 oral mucositis;
however, the majority of pediatric cases were low-grade (Grade 2;
n ¼ 11, observed in cycles 1 and 2) and tended to improve during
subsequent cycles of therapy [9].
Bowel perforation has been described as an infrequent and
life-threatening side effect of temsirolimus in adults [5,6]. Two cases
of perforation were diagnosed in the phase III trial of temsirolimus
for renal cell carcinoma, one in the temsirolimus arm and one in the
combination (temsirolimus plus IFN-a) arm. An additional seven
cases, including four fatalities, were identiﬁed in the temsirolimus
safety database [5]. Bowel perforationwas associated in one autopsy
study with Grade IV mucositis in the affected patient and the
continued use of temsirolimus was cautioned in patients who
experienced severe mucositis. To date, no reports of bowel perfo-
ration associated with temsirolimus use in the pediatric patient
population have been published in the indexed literature.1. Case description
A 17-year-old male undergoing treatment for relapsed testicular
embryonal rhabdomyosarcomawith temsirolimus, vinorelbine, and
cyclophosphamide (ARST0921) presented with acute onset ofnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Computed tomography with intravenous contrast of the patient upon presentation (A: ascites; B: extraluminal free air; C/D; bowel wall thickening and pneumatosis.).
M.A. Herrin et al. / J Ped Surg Case Reports 3 (2015) 320e323 321severe abdominal pain, fever, nausea, and non-bloody, non-bilious
emesis. His past oncologic history was characterized by a
radical inguinal orchiectomy for the removal of a large left testicular
mass 4 years previously. Pathology revealed embryonalFig. 2. Surgical pathology (A: Segment of ileum showing focal ulceration; B: Site of ulce
pseudomembrane formation (arrow, H&E 40); D: Site of ulcer with Gram positive spore frhabdomyosarcoma, spindle cell variant, with evidence of lym-
phovascular invasion. Additional staging via bilateral bone marrow
biopsies, left inguinal node biopsy, chest CT scan, and bone scan
were negative and he was characterized as stage II, group II. Heration with transmural gas ﬁlled cysts (H&E 20); C: Congested bowel mucosa with
orming bacilli, consistent with Clostridium Sp. [B&B 400]).
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ARST0331 with vincristine, actinomycin and cyclophosphamide as
well as adjuvant radiotherapy with 36 Gy to the left lower pelvis
and groin. Three years after completion of therapy he presented
with a 12 cm left retroperitoneal mass and concurrent obstructive
uropathy. Gross total resection was performed, pathology indicated
recurrent tumor, and he initiated chemotherapy for relapsed dis-
ease. Due to severe stomatitis and pharyngitis during cycles 1 and 2,
the patient’s temsirolimus dose was reduced and Day 15 temsir-
olimus was omitted over several cycles.
On day #14 of Cycle #11 of ARST0921 the patient presented to
the Emergency Room with diffuse peritonitis. A computed tomog-
raphy (CT) scan demonstrated ascites, free air, ileal inﬂammation
and pneumatosis with perforation into the mesentery (Fig. 1). He
was tachycardic and febrile to 40Cwith aWBC Count of 15,100 cells/
mcl, having recovered from a nadir of 1300 one week prior. Upon
emergent exploratory laparotomy the patient was found to have full
thickness necrosis of the terminal ileum just proximal to the ileo-
cecal valve with perforation of this segment into the mesentery.
Gross pneumatosis was seen extending 10 cm proximal to this area
of perforation. Additionally, a frankly ischemic segment of mid-
ileum was identiﬁed with apparent thrombosis of the distal
branches of mesenteric blood supply. Ileocecectomy and a separate
resection of mid-ileum were performed.
Surgical pathology revealed small bowel with transmural
ischemic necrosis, focal pseudomembrane formation, extensive
intramural pneumatosis, occasional organizing thrombi, focal
myonecrosis of muscularis propria and serosa with ﬁbrinopurulent
exudate (Fig. 2). Stains for microorganisms showed the presence of
Gram positive bacilli with rare terminal spores morphologically
consistent with Clostridial species and blood clutures drawn prior
to surgical intervention grew out Clostridium septicum.
2. Discussion
The mechanism by which temsirolimus causes bowel perfora-
tion has not been fully elucidated. mTOR inhibitors have been found
to modulate cell proliferation, angiogenesis, and immune function
by decreasing the expression of both HIF-1a and HIF-2a and
inhibiting VEGF activity. Bevacizumab, a targeted VEGF inhibitor,
has a well-described association with bowel perforation [11].
Speculated causes include disruption of the coagulation balance
and secondary ischemic thrombosis by induction of Factor III, von
Willebrand factor, and plasminogen activator [12]. Additionally,
inhibition of cellular microcirculation may impair normal mucosal
turnover and repair mechanisms. Because mTOR inhibitors also
inhibit VEGF activity, these mechanisms may be extrapolated to
temsirolimus [6].
Moreover, the unesteriﬁed parent molecule of temsirolimus,
sirolimus, a drug used routinely for immunosuppression following
solid organ transplant, is also frequently associated with gastroin-
testinal complications including oral lesions and small bowel and
colon ulceration and perforation [13]. Sirolimus has been specif-
ically implicated in small bowel perforation when used in combi-
nation with a calcineurin inhibitor [14,15]. Symptomatic ulceration
of the small bowel has been reported in patients treated with
sirolimus, with resolution following discontinuation of the drug
[16]. It is important to note that this patient’s chemotherapy
regimen included two agents in addition to temsirolimus (cyclo-
phosphamide and vinorelbine) both of which have been associated
with gastrointestinal complications in the setting of neutropenic
[17]. Between the years 2004 and 2014, 4 cases of vinorelbine
associated bowel perforation were reported, all in adults and all in
combination with an angiogenesis inhibitor (bevacizumab, imati-
nib) [18,19]. A possible role for these agents contributing to thepathogenesis of small bowel perforation cannot completely be
excluded.
Only 1000 to 3000 cases of C. septicum are reported in the
United States annually, few of which occur in children [20]. A
recent review found that the majority of C. septicum infections in
children occur in the presence of coexistent perturbations in
neutrophil function, as may occur in malignancy or congenital or
cyclic neutropenia, or in the presence of bowel ischemia [20].
Typhlitis or necrotizing enterocolitis of the colon with extensive
involvement of the cecum and ileocecal junction is common in
cases of C. septicum infection which carries with it a 70e80%
mortality [20,21]. It has been proposed that both malignancy and
the immunosuppressant effects of chemotherapy can impair the
immune function and integrity of the gastrointestinal mucosa to
allow penetration and colonization by the species with subse-
quent bloodborne “metastatic” spread [21e23].
In conclusion, we present a 17-year-old male with a history of
temsirolimus therapy for recurrent metastatic rhabdomyosarcoma
who underwent an ileocecectomy and small bowel resection for
small bowel perforation and necrosis, complicated by C. septicum
infection. Several adult reports have linked temsirolimus-related
bowel perforation with mucositis and have proposed that temsir-
olimus mediated VEGF inhibition may cause bowel ischemia. This
ischemia and resulting ulceration/perforation may have provided a
supportive environment for Clostridium septicum superinfection.
Future investigations should further delineate the risk of bowel
perforation and/or superinfection by necrotizing microorganisms
associated with temsirolimus therapy for solid tumors in the pe-
diatric population.
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